US EditionPublished • loading... • Updated
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
Harbour BioMed forecasts up to US$98 million adjusted profit in 2025 driven by recurring licensing revenue and milestone inflows, a sharp rise from US$2.7 million in 2024.
- In a PR Newswire release, Harbour BioMed announced a positive profit alert, expecting total profit between US$88 million and US$95 million for 2025.
- Driven by recurring licensing and milestones, the company said total profit mainly benefited from agreements with Otsuka, Windward Bio, and platform collaborations with AstraZeneca and Bristol Myers Squibb.
- The company highlighted its proprietary platforms when noting total profit is expected between US$88 million and US$95 million, as per the profit alert, without specifying the platforms as drivers.
- Management said it will build on this momentum by attributing the profit milestone to collaborations and R&D, and said it will reinvest into pipeline development.
- The Board cautioned that this is a preliminary assessment based on unaudited management accounts and directed readers to the company website and PR Newswire release for details.
Insights by Ground AI
42 Articles
42 Articles
Bennington Banner+41 Reposted by 41 other sources
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 3, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive profit…
Coverage Details
Total News Sources42
Leaning Left6Leaning Right6Center18Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
L 20%
C 60%
R 20%
Factuality
To view factuality data please Upgrade to Premium
